Related Experiment Video
Updated: May 10, 2025
07:22
Isolation and Differentiation of Stromal Vascular Cells to Beige/Brite Cells
Published on: March 28, 2013
38.6K
Balancing Promise and Uncertainty: PPAR Agonists in IBD Therapy.
Qurat Ul Ain Iftikhar1, Muhammad Khubaib Iftikhar1, Javed Iqbal2
1Islamic International Medical College, Riphah International University, Rawalpindi, Pakistan.
Journal of Gastroenterology and Hepatology
|April 22, 2025
Summary
Peroxisome proliferator-activated receptor (PPAR) agonists show promise for inflammatory bowel disease (IBD) by reducing gut inflammation. Further research is needed to address model limitations and safety for clinical use.
Area of Science:
- Gastroenterology
- Immunology
- Microbiology
Background:
- Peroxisome proliferator-activated receptor (PPAR) agonists (PPARγ/β/δ) are investigated for inflammatory bowel disease (IBD) treatment due to immunomodulatory and gut microbiota-influencing properties.
- Li et al. studied PPAR agonists in dextran sodium sulfate (DSS)-induced colitis, observing reduced colonic inflammation and beneficial microbiota alterations.
Discussion:
- Limitations of DSS-induced colitis as a chronic model and lack of long-term data require attention.
- Alternative therapies like probiotics and diet show comparable microbiota-modulating and anti-inflammatory effects, necessitating comparative studies.
- Systemic effects and safety profiles of PPAR agonists, especially in patients with metabolic conditions, need thorough evaluation.
Key Insights:
- PPAR agonists demonstrate potential in mitigating DSS-induced colitis.
- Favorable shifts in gut microbiota composition were observed.
- Methodological considerations and safety concerns warrant further investigation before clinical application.
Outlook:
- Future research should prioritize chronic colitis models and human trials for robust clinical translation.
- Precision medicine approaches are needed to personalize PPAR-targeted therapies.
- Comprehensive studies integrating host metabolism, immune regulation, and microbiota are crucial for establishing the role of PPAR agonists in IBD management.
Keywords:
DSS‐induced colitisPPAR agonistsgut microbiotaimmunomodulationinflammatory bowel diseaseprecision medicinetherapeutic interventionsMore Related Videos
Related Concept Videos
01:29Inflammatory Bowel Disease IV: Pharmacological Management
80
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
80
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
86
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
86
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
101
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
101
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
97
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
97
01:29Drugs for Treatment of Ulcerative Colitis in IBD
102
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
102
01:30Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
236
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
236